Event Information

Time：October 24, 2014 (Friday) 10:00-12:00

Place：TRPMA Conference Room
（1F, No. 465-1, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 11557, Taiwan）

The TRPMA invited Ms Lou Shu-Hui, the Chief of the Industry Information Section of the DCB, to give a speech on Oct. 24. Ms Lou has professional expertise in international biopharmaceutical trends. She has been invited to give speeches on biopharmaceutical trends in various events and conferences and was involved in the publication of the award-winning “Biotech Industry Annual”. Ms Lou firstly gave an introduction of the current status of the global and the south-east Asian pharmaceutical markets. According to the DCB’s data, the south-east Asia will be comparatively younger than the rest of the world as the global population is ageing. Therefore, the common diseases and needs for drugs in the south-east Asian countries will be different from the rest of the world. The data suggests that the global drug market will continue growing, especially in the pharmerging market.

The US authority has formulated and announced important regulations to encourage new drug R&D, including the Breakthrough Therapy Designation. Ms Lou gave a few examples of the breakthrough new drugs, such as the development of Eylea for treating wet macular degeneration. She mentioned the developer’s acquisition history and market tactics. Ms Lou also predicted that the healthcare industry is moving towards personalized healthcare.

At the end of the speech, Ms Lou analysed the drug market in Indonesia, Thailand, Vietnam, Philippines, Malaysia and Singapore respectively, covering generic drugs, patented drugs and the growth rates of domestic drug companies and international drug companies. She advised those who intend to enter the south-east Asian market to consider the factors affecting each individual country, such as the demographics, total population, the government’s policies for foreign companies, etc. Ms Luo also compared the ten major drug categories in each country, as well as the return on investment and market risk in the pharmaceutical industry.

Finally, Ms Luo suggested that the industry should make good use of the government’s resources and industry information databank to fund their R&D and support the formulation of market planning. It will help the industry save time and money.

Ms Luo’s speech is very informative. We are looking forward to inviting her for another talk in the future.

The TRPMA invited Ms Lou Shu-Hui, the Chief of the Industry Information Section of the DCB, to give a speech on the “Analysis of the global and the south-east Asian drug markets”.